TGFB1 and idiopathic pulmonary fibrosis: Studies have shown that treprostinil activates cAMP, thereby inhibiting tumor growth factor (TGF-β1) secretion and platelet-derived growth factor (PDGF-BB)-induced cell proliferation, and has antifibrotic effects in idiopathic pulmonary fibrosis (IPF) (53).